Influenza in the intensive care unit

Journal of Intensive Care Medicine

Volumn 18, Issue 2, 2003, Pages 80-91

  Oliveira, Eduardo C ^a   Lee, Burton ^b   Colice, Gene L ^b  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Influenza; Intensive care unit; Nosocomial; Pneumonia

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT;

CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE ASSOCIATION; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UNSPECIFIED SIDE EFFECT; CAUSE OF DEATH; CROSS INFECTION; EPIDEMIC; INFECTION CONTROL; INTENSIVE CARE; METHODOLOGY; PRIMARY PREVENTION; STATISTICS; TREATMENT OUTCOME; VIROLOGY; VIRUS PNEUMONIA;

ANTIVIRAL AGENTS; CAUSE OF DEATH; CROSS INFECTION; DISEASE OUTBREAKS; HUMANS; INFECTION CONTROL; INFLUENZA, HUMAN; INTENSIVE CARE; INTENSIVE CARE UNITS; MORBIDITY; PNEUMONIA, VIRAL; PRIMARY PREVENTION; TREATMENT OUTCOME;

EID: 2942650549     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066602250368     Document Type: Review

References (110)

1. CDC. Update: Influenza activity-United States, 1999-2000 season. MMWR. 2000;49:173-177.
2. Neuzil MK, Reed GW, Mitchel FE, et al. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA. 1999;281:901-907.
3. Barker WH, Mullooly JP. Pneumonia and influenza during epidemics. Arch Intern Med. 1992;142:85-89.
4. Kendal AP, Skehel JJ, Pereira MS. Concepts and Procedures for Laboratory-Based Influenza Surveillance. Atlanta, Ga: Centers for Disease Control; 1982.
5. Douglas RG. Prophylaxis and treatment of influenza. N Engl J Med. 1990;322:443-450.
6. Hayden FG, Sperber SJ, Belshe RB, et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother. 1991;35:1741-1747.
7. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240-1246.
8. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infection. N Engl J Med. 1997;337:875-880.
9. Treanor JJ. Influenza virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia, Pa: Churchill Livingstone; 2000:1823-1819.
10. Ziegler T, Cox NJ. Manual of Clinical Microbiology. Washington, DC: American Society of Microbiology Press; 1999.
11. Alford RH, Kasel JA, Gerome PJ, et al. Human influenza resulting from aerosol inhalation. Proc Soc Biol Med. 1966;122:800-804.
12. Moser MR, Bender TR, Margolis HS, et al. An outbreak of influenza aboard a commercial airline. Am J Epidemiol. 1979;110:1-6.
13. Loosli CG, Lemon HM, Robertson OH, et al. Experimental airborne influenza infection: influence of humidity on surviral of virus in air. Proc Soc Exp Biol Med. 1943;53:205-206.
14. Bean B, Moore BM, Sterner B, et al. Survival of influenza viruses on environmental surfaces. J Infect Dis. 1982;146:47-52.
15. Douglas RG. Influenza in man. In: Kilbourne ED, ed. The Influenza Virus and Influenza. New York: Academic Press; 1975:395-447.
16. Monto AS, Kioumehr F. The Tecumseh Study of Respiratory Illness: IX. Occurrence of influenza in the community, 1966-1971. Am J Epidemiol. 1975;102:553-563.
17. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev. 1982;4:24-44.
18. Glezen WP, Keitel WA, Taber LH, et al. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am Epidemiol. 1991;133:296-304.
19. Baker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol. 1980;112:798-813.
20. Glezen WP, Couch RB, Six HR. The influenza herald wave. Am J Epidemiol. 1982;116:589-598.
21. Bean B, Rhame FS, Hughes KS, et al. Influenza B: hospital activity during a community epidemic. Diag Microbiol Infect Dis. 1983;1:177-183.
22. Hoffman PC, Dixon RE. Control of influenza in the hospital. Ann Intern Med. 1977;7:725-728.
23. Hall CB, Douglas RG Jr. Nosocomial influenza as a cause of intercurrent fever in infants. Pediatrics. 1975;55:673-677.
24. Arden NH, Patriarca PA, Fasano MB, et al. The role of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med. 1988;148:865-868.
25. Arroyo JC, Postic B, Brown A, et al. Influenza A/Philippines/2/82 outbreak in a nursing home: limitations of influenza vaccination in the elderly. Am J Infect Control. 1984;12:329-334.
26. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during influenza A (H3N2) epidemic. JAMA. 1985;253:1136-1139.
27. Walsh JJ, Dietlein LF, Low FN, et al. Bronchotracheal response in human influenza. Arch Intern Med. 1961;108:376-388.
28. Little JW, Hall WJ, Douglas RG Jr, et al. Airway hyperreactivity and peripheral airway dysfunction in influenza A infection. Am Rev Respir Dis. 1978;118:295-303.
29. Hall WJ, Douglas RG Jr, Hyde RW, et al. Pulmonary mechanics after uncomplicated influenza A infection. Am Rev Respir Dis. 1976;113:141-147.
30. Hayden FG, Fritz RS, Lobo MC, et al. Local and systemic cytokine responses during experimental human influenza A virus infection. J Clin Invest. 1998;101:643-619.
31. Louria DB, Dlummenfeld HL, Ellis JT, Kilbourne ED, et al. Studies in the pandemic of 1957-1958: pulmonary complications of influenza. J Clin Invest. 1959;38:213-265.
32. Lindsay MI, Hermann EC, Morrow GW, et al. Hong Kong influenza: clinical, microbiologic, and pathologic features in 127 cases. JAMA. 1970;214:1825-1832.
33. Schwarzmann SW, Adler JL, Sullivan KJ, et al. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med. 1971;127:1037-1041.
34. Hers JF, Mulder J. Broad aspects of the pathology and pathogenesis of human influenza. Am Rev Respir Dis. 1961;83:84-94.
35. Katzenstein AA. Infection: I. Unusual pneumonias. In: Katzenstein A, Askin FB, eds. Surgical Pathology of Non-Neoplastic Lung Disease. Philadelphia, Pa: W. B. Saunders; 1997:248-260.
36. Noble R, Lillington GA, Kempson RL. Fatal influenza pneumonia: premoitem diagnosis by lung biopsy. Chest. 1973;63:644-646.
37. Yeldandi AV, Colby TV. Pathologic features of lung biopsy specimens from influenza pneumonia cases. Hum Pathol. 1994;25:47-53.
38. Tamura H, Aronson BE. Intranuclear fibrillary inclusions in influenza pneumonia. Arch Pathol Lab Med. 1978;102:252-257.
39. Scheiblauer H, Reinacher M, Tashiro M, et al. Interactions between bacteria and influenza A virus in the development of influenza pneumonia. J Infect Dis. 1992;166:783-791.
40. Tashiro M, Ciborowski P, Klenk HD, et al. Role of staphylococcus protease in the development of influenza pneumonia. Nature. 1987;325:536-537.
41. Pang G, Clancy R, Cong MA, et al. Influenza virus inhibits lisozyme secretion by sputum neutrophils in subjects with chronic bronchial sepsis. Am J Respir Crit Care Med. 2000;161:718-722.
42. MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infection. Lancet. 1998;352:1877-1881.
43. Oliveira E, Marik P, Colice G. Influenza pneumonia: a descriptive study. Chest. 2001;119:1717-1723.
44. Chickering HT, Park JH. Staphylococcus aurcus pneumonia. JAMA. 1919;72:617-626.
45. Kilbourne ED. Studies on influenza in the pandemic of 1957-1958: isolation of influenza A (Asian strain) viruses from influenza patients with pulmonary complications. J Clin Invest. 1959;38:266-273.
46. Petersdorf RG, Fusco JJ, Harter DH, et al. Pulmonary infections complicating Asian influenza. Arch Intern Med. 1959;103:262-272.
47. Ljungman P, Anderson J, Aschan J, et al. Influenza A in immunocompromised patients. Clin Infect Dis. 1993;17:244-247.
48. Yousuf HM, Englund J, Couch R, et al. Influenza among hospitalized adults with leukemia. Clin Infect Dis. 1997;24:1095-1099.
49. Yuen KY, Chan PKS, Tsang DNC, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1. Lancet. 1998;351:467-471.
50. Martin CM, Kunin CM, Gottlieb LS, Finland M. Asian influenza A in Boston, 1957-1958: severe staphylococcal pneumonia complicating influenza. Arch Intern Med. 1959;103:532-541.
51. Nicholson KG. Clinical features of influenza. Semin Resp Infect. 1992;7:26-37.
52. Connoly AM, Salmon RL, Lervy B, et al. What are the complications of influenza and can they be prevented? Lessons from the 1989 epidemic of H3N2 influenza A in general practice. BMJ. 1993;306:1452-1454.
53. Greco TP, Askenase PW, Kashgarian M. Postviral myositis: myxovirus-like structures in affected muscle. Ann Intern Med. 1977;86:193-198.
54. Edelen JS, Bender TR, Chin TDY. Encephalopathy and pericarditis during an outbreak of influenza. Am J Epidemiol. 1974;100:79-83.
55. Middleton PJ, Alexander RM, Szymanski MT. Severe myositis during recovery from influenza. Lancet. 1970;2:533.
56. Simon NM. Acute myoglobinuria associated with type A2 influenza. JAMA. 1970;212:1704-1707.
57. Dietzman DE, Schaller JG, Ray CG, et al. Acute myositis associated with influenza B infection. Pediatrics. 1976;57:255-258.
58. MacDonald KL, Osterholm MT, Hedberg CW, et al. Toxic shock syndrome: a newly recognized complication of influenza and influenza like illness. JAMA. 1987;257:1053-1058.
59. Sperber SJ, Francis JH. Toxic shock during an influenza outbreak. JAMA. 1987;257:1086-1089.
60. Cartwright KA, Jones DM, Smith AJ, et al. Influenza A and meningococcal disease. Lancet. 1991;338:554-557.
61. Consensus Development Conference. Diagnosis and treatment of Reye's syndrome. JAMA. 1981;246:2441.
62. Corey L, Rubin RJ, Bregmen D, et al. Diagnostic criteria for influenza B-associated Reye's syndrome: clinical vs. pathologic criteria. Pediatrics. 1977;60:602.
63. Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med. 1973;288:498-505.
64. Glezen WP. Consideration of the risk of influenza in children and indicators for prophylaxis. Rev Infect Dis. 1980;2:408-420.
65. Leonardi GP, Leib H, Birkhead GS, et al. Comparison of rapid detection methods for influenza A virus and their value in health-care management of institutionalized geriatric patients. J Clin Microbiol. 1994;32:70-74.
66. Doller G, Schuy W, Tjhen KY, et al. Direct detection of influenza virus antigen in nasopharyngeal specimens by direct enzyme immunoassay in comparison with quantitating virus shedding. J Clin Microbiol. 1992;30:886-889.
67. Ryan-Poirier KA, Katz JM, Webster RG, Kawaoka Y. Application of Directigen Flu-A for the detection of influenza A virus in human and nonhuman specimens. J Clin Microbiol. 1992;30:1072-1075.
68. Kaiser L, Brioles MS, Hayden FG. Performance of virus isolation and Directigen Flu-A to detect influenza A virus in experimental human infection. J Clin Virol. 1999;14:191-197.
69. Carrat F, Tachet A, Housset B, et al. Influenza and influenza-like illness in general practice: drawing lessons for surveillance from a pilot study in Paris, France. Br J Gen Pract. 1997;47:217-220.
70. Waris M, Ziegler T, Kivivirta M, et al. Rapid detection of respiratory syncytial virus and influenza A virus in cell cultures by immunoperoxidase staining with monoclonal antibodies. J Clin Microbiol. 1999;28:1159-1162.
71. Anonymous. The Medical Letter, Inc. 1999;41:121-122.
72. The ARDS Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301-1308.
73. Oseasohn R, Adelson L, Kaji M. Clinicopathologic study of thirty-three fatal cases of Asian influenza. N Engl J Med. 1959;269:510-518.
74. Martin CM, Kunin CM, Gottlieb LS, et al. Asian influenza A in Boston, 1957-1958: observation in thirty two influenza-associated fatal cases. Arch Intern Med. 1959;103:515-531.
75. Whimbey E, Elting LS, Couch RB, Lo W, et al. Influenza A virus infections among hospitalized adult bone marrow transplant patients. Bone Mar Trans. 1994;13:437-440.
76. Giles C, Shuttleworth EM. Post-mortem findings in 46 influenza deaths. Lancet. 1957;2:1224-1225.
77. Feldman PS, Cohan MA, Hierholzer WJ. Fatal Hong Kong influenza: a clinical, microbiological and pathological analysis of nine cases. Yale J Biol Med. 1972;45:49-63.
78. Klimek JJ, Lindenberg LB, Cole S, et al. Fatal case of influenza pneumonia with suprainfection by multiple bacteria and Herpes simplex virus. Am Rev Respir Dis. 1976;113:683-688.
79. CDC. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 1999;46:1-28.
80. CDC. Neuraminidase Inhibitors for the treatment of influenza A and B infections. MMWR. 1999;48:1-9.
81. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254-261.
82. Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med. 2000;342:661-662.
83. Cox NJ, Hughes JM. New options for the prevention of influenza. N Engl J Med. 1999;341:1387-1388.
84. Blumenfeld HL, Kilbourne ED, Louria DB, et al. Studies on influenza in the pandemic of 1957-1938: an epidemiologic, clinical and serologic investigation of an intra-hospital epidemic, with a note on vaccination efficacy. J Clin Invest. 1959;38:199-212.
85. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, eds. Options for the Control of Influenza. New York: Alan R. Liss; 1986:155-168.
86. Kolber MA, Gabr AH, De La Rosa A, et al. Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. AIDS. 2002;16(4):537-542.
87. Amendola A, Boschini A, Colzani D, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol. 2001;65(4):644-648.
88. Tasker SA, Treanor JJ, Paxton WB, et al. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double blind, placebo-controlled trial. Ann Intern Med. 1999;131(6):430-433.
89. CDC. Influenza and pneumococcal vaccination levels among adults aged ≥ 65 years in the United States. MMWR. 2001;50(25):532-537.
90. U.S. Department of Health and Human Services. Healthy People 2010. Washington, DC: Author, 2000.
91. Buikema AR, Singleton JA, Sneller VP, Strikas RA. Influenza vaccination in nursing homes, Unites States, 1995 and 1997 [Abstract P2-49]. Options for the Control of Influenza: IV. Crete, Greece. September 2000.
92. Adal KA, Flowers RH, Anglin AM, et al. Prevention of nosocomial influenza. Infect Control Hosp Epidemiol. 1996;17:641-648.
93. Palache AM. Influenza vaccine: a reappraisal of their use. Drugs. 1997;54:841-856.
94. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med. 1994;121:947-952.
95. Nichol KL, Margolis KL, Wourema J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331:778-784.
96. Govaert ME, Dinant GJ, Aretz K, et al. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ. 1993;307:988-990.
97. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial. JAMA. 1990;264:1139-1141.
98. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. Arch Intern Med. 1996;156:1546-1550.
99. ALA Asthma Clinical research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med. 2001;345:1529-1536.
100. Neuzil KM, Reed GW, Mitchel EF, et al. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998;148(11):1094-1102.
101. Betts RF. Amantadine and rimantadine for the prevention of influenza A. Semin Respir Infect. 1989;4:304-310.
102. Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin N Am. 1987;1:459-478.
103. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine prophylaxis of influenza infection. N Engl J Med. 1982;307:580-584.
104. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother. 1995;29:299-310.
105. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336-1343.
106. Peters PH, Gravenstein S, Norwood P, et al. Long term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail elderly population. J Am Geriatr Soc. In press.
107. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med. 2000;343(18):1282-1289.
108. Eggiman P, Pittet D. Infection control in the ICU. Chest. 2001;120:2059-2093.
109. Tablan OC, Anderson IJ, Arden NH. Guidelines for prevention of nosocomial pneumonia. Infect Control Hosp Epidemiol. 1994;15:588-625.
110. Garner JS. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol. 1996;17:53-80.